Endo Reports Findings From PK Simulation Modeling Study In Men With Hypogonadism

Endo International plc (ENDP) published data from a population pharmacokinetic modeling and simulation study, evaluating potential dosing flexibility of AVEED (testosterone undecanoate) in hypogonadal males. The company said the pharmacokinetic simulation modeling study predicted more frequent administration with shorter dosing intervals (8 weeks vs. 10 weeks) would reduce serum testosterone fluctuations and elevate testosterone concentrations at the end of each maintenance dosing interval while maintaining acceptable levels of overall testosterone exposure.

AVEED is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Aerospace giant Boeing Co. (BA) on Wednesday reported fourth-quarter net loss attributable to Boeing shareholders of $4.16 billion or $7.02 per share, sharply narrower than $8.44 billion or $14.65 per share in the year-ago quarter. The 787 program recorded $3.5 billion pre-tax non-cash charge; focused... Telecom giant AT&T reported Wednesday a profit for the fourth quarter compared to a loss last year, primarily boosted by continuing customer growth in wireless, fiber and HBO Max, despite a 10 percent drop in revenues. Both adjusted earnings for the quarter and quarterly revenues also topped analysts' expectations. However, the company issued weak earnings and sales growth outlook for fiscal 2022. Bentley Motors, owned by German automaker Volkswagen AG, announced plans to develop its first-ever Battery-Powered Electric Vehicle or BEV in 2025. The British luxury carmaker also plans investment of around 2.5 billion pounds or $3.4 billion in sustainability over the next ten years. The company will develop and build the new vehicles in the UK plant in Crewe.
Follow RTT